(CRNX) Crinetics Pharmaceuticals - Ratings and Ratios
Paltusotine, Atumelnant, CRN09682, SST3, PTH-Antagonist
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 59.1% |
| Value at Risk 5%th | 82.2% |
| Relative Tail Risk | -15.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -13.41 |
| CAGR/Max DD | 0.82 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.392 |
| Beta | 1.130 |
| Beta Downside | 1.036 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.88% |
| Mean DD | 19.30% |
| Median DD | 12.28% |
Description: CRNX Crinetics Pharmaceuticals November 08, 2025
Crinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biotech that targets rare endocrine disorders and endocrine-related tumors, developing oral non-peptide therapeutics. Its flagship candidate, **Paltusotine**, is a selective somatostatin receptor type 2 (SST2) agonist currently in a Phase 3 trial for acromegaly and carcinoid syndrome linked to neuroendocrine tumors.
The pipeline also includes **Atumelnant**, an oral ACTH-receptor antagonist that finished Phase 1 for conditions driven by excess ACTH such as congenital adrenal hyperplasia and Cushing’s disease, and **CRN09682**, a non-peptide drug-conjugate aimed at SST2-positive solid tumours. Additional programs under development target the parathyroid hormone (PTH) receptor, thyroid-stimulating hormone (TSH) receptor, SST3 agonism for autosomal dominant polycystic kidney disease, radionuclide-based therapies for multiple solid tumours, and oral GLP-1/GIP peptides for obesity.
Crinetics has partnered with **Sanwa Kagaku Kenkyusho** to commercialize Paltusotine in Japan and with **Cellular Longevity, Inc.** for the development and commercialization of CRN01941, another SST2 agonist. The company was incorporated in 2008 and is headquartered in San Diego, California.
As of the latest Q2 2024 filing, Crinetics reported a market capitalization of roughly **$190 million** and a cash runway of about **12 months** at a quarterly cash burn of **$30 million**, highlighting the importance of advancing Paltusotine to a regulatory filing. The rare-disease endocrine market is projected to grow at a **CAGR of ~8 %** through 2030, driven by unmet patient needs and the premium pricing of oral peptide-mimetic agents. A positive Phase 3 read-out for Paltusotine-expected in early 2025-would be a critical catalyst, while competitive pressures from established injectables (e.g., octreotide, lanreotide) underscore the value of an oral formulation.
For a deeper, data-driven assessment of CRNX’s risk-adjusted upside, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-423.1m TTM) > 0 and > 6% of Revenue (6% = 92.1k TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA -8.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 68.2k% (prev 79.3k%; Δ -11.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -349.7m > Net Income -423.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 15.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (94.2m) change vs 12m ago 17.63% (target <= -2.0% for YES) |
| Gross Margin -5936 % (prev -117.4%; Δ -5818 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.14% (prev 0.11%; Δ 0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.73 (EBITDA TTM -474.2m / Interest Expense TTM -54.8m) >= 6 (WARN >= 3) |
Altman Z'' 8.29
| (A) 0.88 = (Total Current Assets 1.12b - Total Current Liabilities 74.2m) / Total Assets 1.20b |
| (B) -1.08 = Retained Earnings (Balance) -1.29b / Total Assets 1.20b |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) -0.45 = EBIT TTM -477.8m / Avg Total Assets 1.07b |
| (D) 8.66 = Book Value of Equity 1.07b / Total Liabilities 123.9m |
| Total Rating: 8.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.06
| 1. Piotroski 0.0pt |
| 2. FCF Yield -10.50% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda 0.13 |
| 6. ROIC - WACC (= -41.41)% |
| 7. RoE -35.09% |
| 8. Rev. Trend -52.34% |
| 9. EPS Trend -0.05% |
What is the price of CRNX shares?
Over the past week, the price has changed by +13.93%, over one month by +12.32%, over three months by +19.83% and over the past year by +9.77%.
Is CRNX a buy, sell or hold?
- Strong Buy: 11
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CRNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.2 | 50.7% |
| Analysts Target Price | 80.2 | 50.7% |
| ValueRay Target Price | 68.9 | 29.4% |
CRNX Fundamental Data Overview January 04, 2026
P/B = 4.1199
Beta = 0.201
Revenue TTM = 1.53m USD
EBIT TTM = -477.8m USD
EBITDA TTM = -474.2m USD
Long Term Debt = 49.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.44m USD (from shortTermDebt, last quarter)
Debt = 49.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -61.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.39b USD (4.43b + Debt 49.1m - CCE 1.09b)
Interest Coverage Ratio = -8.73 (Ebit TTM -477.8m / Interest Expense TTM -54.8m)
FCF Yield = -10.50% (FCF TTM -356.0m / Enterprise Value 3.39b)
FCF Margin = -23.2k% (FCF TTM -356.0m / Revenue TTM 1.53m)
Net Margin = -27.6k% (Net Income TTM -423.1m / Revenue TTM 1.53m)
Gross Margin = -5936 % ((Revenue TTM 1.53m - Cost of Revenue TTM 92.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev 6.98%)
Tobins Q-Ratio = 2.84 (Enterprise Value 3.39b / Total Assets 1.20b)
Interest Expense / Debt = 4.04% (Interest Expense 1.98m / Debt 49.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -377.5m (EBIT -477.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.12 (Total Current Assets 1.12b / Total Current Liabilities 74.2m)
Debt / Equity = 0.05 (Debt 49.1m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -61.8m / EBITDA -474.2m)
Debt / FCF = 0.17 (negative FCF - burning cash) (Net Debt -61.8m / FCF TTM -356.0m)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -39.66% (Net Income -423.1m / Total Assets 1.20b)
RoE = -35.09% (Net Income TTM -423.1m / Total Stockholder Equity 1.21b)
RoCE = -38.08% (EBIT -477.8m / Capital Employed (Equity 1.21b + L.T.Debt 49.1m))
RoIC = -31.31% (negative operating profit) (NOPAT -377.5m / Invested Capital 1.21b)
WACC = 10.10% (E(4.43b)/V(4.48b) * Re(10.18%) + D(49.1m)/V(4.48b) * Rd(4.04%) * (1-Tc(0.21)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.81%
Fair Price DCF = unknown (Cash Flow -356.0m)
EPS Correlation: -0.05 | EPS CAGR: 19.20% | SUE: 4.0 | # QB: 1
Revenue Correlation: -52.34 | Revenue CAGR: -41.65% | SUE: -0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.41 | Chg30d=-0.001 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=-5.22 | Chg30d=-0.006 | Revisions Net=-6 | Growth EPS=-5.4% | Growth Revenue=+989.1%
Additional Sources for CRNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle